Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
|Articles|June 1, 2002
Molecule engineered to target neovascularization in AMD
A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Advertisement
Advertisement
Related to this article
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Duravyu misses wet AMD end point again as EyePoint pivots to DME
3
A vascular link: erectile dysfunction may signal glaucoma risk in men
4
The Retina TL;DR with Dr. Weng: Thriving in fellowship with Amer Alsoudi, MD, and Monia Reding, MD
5